Table 1.
Description of the Cohort by Each of the 4 Time Periods After PCI and by DAPT Use Within 4 Time Periods After PCI
| Variable | Months 1–5 (n=40 882) | Months 6–9 (n=38 041) | Months 10–12 (n=35 274) | Months 13–18 (n=28 361) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAPT discontinued | On DAPT | DAPT discontinued | On DAPT | DAPT discontinued | On DAPT | DAPT discontinued | On DAPT | |||||||||
| (n=2351) | (n=38 531) | (n=2408) | (n=35 633) | (n=6667) | (n=28 607) | (n=12 408) | (n=15 953) | |||||||||
| Age, mean (SD), y | 65.5 | (9.9) | 65.5 | (8.7) | 65.9 | (9.8) | 65.8 | (8.6) | 65.9 | (8.6) | 66.0 | (8.6) | 66.1 | (8.8) | 66.5 | (8.4) |
| Men, n (%) | 2318 | (98.6) | 37 894 | (98.4) | 2367 | (98.3) | 35 043 | (98.3) | 6545 | (98.2) | 28 144 | (98.4) | 12 210 | (98.4) | 15 690 | (98.4) |
| Acute coronary syndrome at index PCI, n (%) | 244 | (10.4) | 5151 | (13.4)* | 435 | (18.1) | 6196 | (17.4) | 1010 | (15.2) | 5916 | (20.7)* | 2400 | (19.3) | 4422 | (27.7)* |
| Current smoker, n (%) | 913 | (38.8) | 12 643 | (32.8)* | 911 | (37.8) | 11 566 | (32.5)* | 2159 | (32.4) | 9297 | (32.5) | 4142 | (33.4) | 5070 | (31.8) |
| Former smoker, n (%) | 1030 | (43.8) | 18 706 | (48.6)* | 1065 | (44.2) | 17 384 | (48.8)* | 3314 | (49.7) | 13 891 | (48.6) | 5906 | (47.6) | 7849 | (49.2) |
| Comorbidities, n (%) | ||||||||||||||||
| Anemia | 611 | (26.0) | 8556 | (22.2)* | 664 | (27.6) | 8273 | (23.2)* | 1457 | (21.9) | 7028 | (24.6)* | 3095 | (24.9) | 4257 | (26.7)† |
| Angina | 980 | (41.7) | 17 952 | (46.6)* | 1158 | (48.1) | 17 201 | (48.3) | 2927 | (43.9) | 14 477 | (50.6)* | 5882 | (47.4) | 8922 | (55.9)* |
| Congestive heart failure | 792 | (33.7) | 10 898 | (28.3)* | 828 | (34.4) | 10 298 | (28.9)* | 1757 | (26.4) | 8622 | (30.1)* | 3538 | (28.5) | 5307 | (33.3)* |
| Chronic kidney disease | 496 | (21.1) | 7721 | (20.0) | 554 | (23.0) | 7324 | (20.6)† | 1244 | (18.7) | 6152 | (21.5)* | 2568 | (20.7) | 3759 | (23.6)* |
| COPD | 848 | (36.1) | 12 755 | (33.1)† | 846 | (35.1) | 12 096 | (34.0) | 2145 | (32.2) | 10 053 | (35.1)* | 4244 | (34.2) | 5962 | (37.4)* |
| Diabetes on insulin | 944 | (40.2) | 15 920 | (41.3) | 1013 | (42.1) | 14 841 | (41.7) | 2536 | (38.0) | 12 239 | (42.8)* | 4926 | (39.7) | 7334 | (46.0)* |
| Diabetes on oral treatment | 906 | (38.5) | 16 397 | (42.6)* | 978 | (40.6) | 15 391 | (43.2)† | 2676 | (40.1) | 12 671 | (44.3)* | 5176 | (41.7) | 7559 | (47.4)* |
| Hypertension | 2180 | (92.7) | 36 340 | (94.3)† | 2259 | (93.8) | 33 852 | (95.0) | 6269 | (94.0) | 27 362 | (95.7)* | 11 801 | (95.1) | 15 446 | (96.8)* |
| Peripheral artery disease | 204 | (8.7) | 2883 | (7.5) | 212 | (8.8) | 2765 | (7.8) | 424 | (6.4) | 2365 | (8.3)* | 798 | (6.4) | 1644 | (10.3)* |
| Cancer and chemotherapy or radiotherapy | 89 | (3.8) | 1667 | (4.3) | 145 | (6.0) | 1574 | (4.4)* | 313 | (4.7) | 1312 | (4.6) | 578 | (4.7) | 777 | (4.9) |
| History, n (%) | ||||||||||||||||
| Prior myocardial infarct | 234 | (10.0) | 2800 | (7.3)* | 217 | (9.0) | 2496 | (7.0)† | 366 | (5.5) | 2052 | (7.2)* | 703 | (5.7) | 1303 | (8.2)* |
| Prior PCI | 204 | (8.7) | 2564 | (6.7)† | 177 | (7.4) | 2337 | (6.6) | 313 | (4.7) | 1984 | (6.9)* | 621 | (5.0) | 1339 | (8.4)* |
| Prior CABG | 85 | (3.6) | 1330 | (3.5) | 78 | (3.2) | 1236 | (3.5) | 186 | (2.8) | 1039 | (3.6)† | 332 | (2.7) | 694 | (4.4)* |
| Prior stroke | 82 | (3.5) | 1081 | (2.8) | 87 | (3.6) | 959 | (2.7) | 128 | (1.9) | 801 | (2.8)* | 305 | (2.5) | 480 | (3.0)† |
| Prior major bleed | 115 | (4.9) | 1402 | (3.6)† | 114 | (4.7) | 1238 | (3.5)† | 208 | (3.1) | 1003 | (3.5) | 405 | (3.3) | 568 | (3.6) |
| Medications, n (%) | ||||||||||||||||
| Aspirin (VA prescribed) | 2271 | (96.6) | 37 222 | (96.6) | 1220 | (50.7) | 19 398 | (54.4)† | 2962 | (44.4) | 14 275 | (49.9)* | 5608 | (45.2) | 8971 | (56.2)* |
| Oral anticoagulant | 227 | (9.7) | 3778 | (9.8) | 265 | (11.0) | 2907 | (8.2)* | 605 | (9.1) | 2169 | (7.6)* | 1220 | (9.8) | 1074 | (6.7)* |
| ACE inhibitor | 1534 | (65.3) | 24 687 | (64.1) | 1221 | (50.7) | 19 601 | (55.0)* | 3264 | (49.0) | 15 093 | (52.8)* | 6031 | (48.6) | 8791 | (55.1)* |
| Angiotensin receptor blocker | 296 | (12.6) | 6090 | (15.8)* | 281 | (11.7) | 5481 | (15.4)* | 936 | (14.0) | 4454 | (15.6)† | 1840 | (14.8) | 2801 | (17.6)* |
| β‐Blocker | 2165 | (92.1) | 35 802 | (92.9) | 1835 | (76.2) | 30 731 | (86.2)* | 5307 | (79.6) | 24 268 | (84.8)* | 9948 | (80.2) | 14 175 | (88.9)* |
| Calcium channel blocker | 743 | (31.6) | 13 672 | (35.5)† | 607 | (25.2) | 10 148 | (28.5)† | 1763 | (26.4) | 8017 | (28.0)† | 3343 | (26.9) | 4944 | (31.0)* |
| Statin | 2256 | (96.0) | 37 506 | (97.3)* | 1956 | (81.2) | 32 902 | (92.3)* | 5831 | (87.5) | 25 806 | (90.2)* | 10 735 | (86.5) | 14 867 | (93.2)* |
| Antilipemic other | 171 | (7.3) | 3777 | (9.8)* | 147 | (6.1) | 2731 | (7.7)† | 417 | (6.3) | 2078 | (7.3)† | 722 | (5.8) | 1388 | (8.7)* |
| Antiarrhythmic | 112 | (4.8) | 1310 | (3.4)† | 81 | (3.4) | 914 | (2.6) | 166 | (2.5) | 691 | (2.4) | 300 | (2.4) | 443 | (2.8) |
| Diuretic | 1007 | (42.8) | 17 407 | (45.2) | 867 | (36.0) | 13 233 | (37.1) | 2195 | (32.9) | 10 524 | (36.8)* | 4218 | (34.0) | 6521 | (40.9)* |
| NSAID | 361 | (15.4) | 7495 | (19.5)* | 229 | (9.5) | 4331 | (12.2)† | 680 | (10.2) | 3094 | (10.8) | 1258 | (10.1) | 2275 | (14.3)* |
| Protein pump inhibitor | 1120 | (47.6) | 20 480 | (53.2)* | 876 | (36.4) | 14 834 | (41.6)* | 2488 | (37.3) | 11 427 | (39.9)* | 4771 | (38.5) | 7002 | (43.9)* |
| Blood values, mean (SD) | ||||||||||||||||
| eGFR, mL/min | 75 | (23.4) | 75 | (20.6) | 73 | (23.4) | 74 | (20.8) | 74 | (20.6) | 73 | (21.0)* | 74 | (21.0) | 72 | (21.1)* |
| Glucose, mg/dL | 133 | (47.7) | 132 | (45.2) | 132 | (55.5) | 131 | (49.6) | 129 | (50.4) | 131 | (52.4)† | 129 | (51.6) | 133 | (49.7)* |
| Hemoglobin, g/dL | 13.3 | (1.8) | 13.5 | (1.6)* | 13.3 | (1.9) | 13.6 | (1.6)* | 13.7 | (1.7) | 13.7 | (1.6) | 13.7 | (1.7) | 13.7 | (1.6)† |
| White cell count, 1000/mm3 | 8.0 | (2.8) | 7.8 | (2.5)* | 7.7 | (2.9) | 7.6 | (2.5) | 7.5 | (2.8) | 7.6 | (2.5) | 7.5 | (2.4) | 7.5 | (2.7) |
| Platelet count, 1000/mm3 | 211 | (64) | 206 | (58)* | 213 | (66) | 208 | (59)† | 211 | (63) | 209 | (60) | 211 | (61) | 209 | (59) |
| LDL cholesterol, mg/dL | 96 | (36) | 88 | (32)* | 89 | (37) | 81 | (31)* | 82 | (32) | 80 | (31)* | 81 | (33) | 78 | (30)* |
| HDL cholesterol, mg/dL | 40 | (12) | 39 | (11) | 40 | (12) | 39 | (11) | 40 | (11) | 40 | (11)* | 40 | (12) | 40 | (11)* |
| Troponin, ng/mL | 3.2 | (12.9) | 2.5 | (9.5)† | 2.2 | (7.8) | 2.2 | (9.1) | 1.9 | (7.8) | 2.0 | (8.8) | 1.9 | (7.9) | 1,8 | (3, 8) |
| N‐terminal ProB‐type natriuretic peptide, pg/mL | 404.7 | (839.6) | 261.8 | (661.1)* | 352.0 | (742.2) | 241.2 | (653.7)* | 240.5 | (827.3) | 232.6 | (644.2) | 213.4 | (451.9) | 238.6 | (776.4) |
ACE indicates angiotensin‐converting enzyme inhibitor; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; PCI, percutaneous coronary intervention; and VA, Veterans Affairs.
*P<0.001, † P<0.01 (comparisons within each time frame).